--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Adamis Pharmaceuticals Corporation 8-K [adamis-8k_1209.htm]
 
 
Exhibit 10.2
 
 
AMENDMENT TO ADAMIS PHARMACEUTICALS CORPORATION
CONVERTIBLE PROMISSORY NOTE

 
Adamis Pharmaceuticals Corporation, a Delaware corporation, and The G-Max Trust
(the “Lender”), hereby agree, effective as of December 30, 2010 to amend the
Convertible Promissory Note issued to Lender on December 29, 2009 by extending
the Maturity Date of the Note from December 31, 2010 to March 31, 2011.

In the event of any inconsistency between the terms of this Amendment and the
terms of the Note, the terms of this Amendment shall control.  Except to the
extent expressly amended pursuant to this Amendment, the terms and provisions of
the Note, as amended, shall remain in full force and effect without
modification.  Capitalized terms used herein but not defined herein shall have
the meanings ascribed to those terms in the Note.  This Amendment may be
executed in one or more counterparts, each of which shall be an original and all
of which shall together constitute one and the same document.  This Amendment
shall be governed by the laws of the State of California, notwithstanding its
conflict of laws provisions.

[SIGNATURE PAGE TO FOLLOW]

 
 

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have executed this Amendment to Convertible
Promissory Note as of the date first above written.

LENDER:
 
THE G-MAX TRUST
       
By:   
/s/ Christof Boo and Franchesca Boo
       
Its:
Trustees
 

ADAMIS PHARMACEUTICALS CORPORATION:
       
By:   
/s/ Dennis J. Carlo
       
Its:
Chief Executive Officer
 

[SIGNATURE PAGE TO AMENDMENT TO 10% SENIOR SECURED CONVERTIBLE NOTE]